BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37105561)

  • 1. Mycosis fungoides and Sézary syndrome.
    Lee H
    Blood Res; 2023 Apr; 58(S1):66-82. PubMed ID: 37105561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
    Giordano A; Pagano L
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.
    Miyashiro D; Sanches JA
    Front Oncol; 2023; 13():1141108. PubMed ID: 37124514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
    Oka T; Miyagaki T
    Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
    Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
    An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis fungoides.
    Zinzani PL; Ferreri AJ; Cerroni L
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome.
    Liu Z; Wu X; Hwang ST; Liu J
    Ann Dermatol; 2021 Dec; 33(6):487-496. PubMed ID: 34858000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
    Suzuki SY; Ito K; Ito M; Kawai K
    J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.